These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 28976864)

  • 1. Per-Protocol Analyses of Pragmatic Trials.
    Hernán MA; Robins JM
    N Engl J Med; 2017 Oct; 377(14):1391-1398. PubMed ID: 28976864
    [No Abstract]   [Full Text] [Related]  

  • 2. Patients and investigators prefer measures of absolute risk in subgroups for pragmatic randomized trials.
    Murray EJ; Caniglia EC; Swanson SA; Hernández-Díaz S; Hernán MA
    J Clin Epidemiol; 2018 Nov; 103():10-21. PubMed ID: 29966732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulary restrictions may impact enrollment in pragmatic trials and limit generalizability of findings to vulnerable populations.
    Segal JB;
    Clin Trials; 2020 Dec; 17(6):729-731. PubMed ID: 32650667
    [No Abstract]   [Full Text] [Related]  

  • 4. Lessons learned in methods and analyses for pragmatic studies.
    Eckardt P; Erlanger AE
    Nurs Outlook; 2018 Sep; 66(5):446-454. PubMed ID: 30131168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the design of pragmatic trials: key issues remain.
    Caro JJ; Ishak KJ
    J Comp Eff Res; 2012 Jul; 1(4):319-27. PubMed ID: 24237466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Including or excluding data: intention-to-treat and completer analyses].
    Böhnke JR; Lutz W
    Psychother Psychosom Med Psychol; 2012 Nov; 62(11):429. PubMed ID: 23143830
    [No Abstract]   [Full Text] [Related]  

  • 7. The shrinking scope of pragmatic trials: a methodological reflection on their domain of applicability.
    Pawson R
    J Clin Epidemiol; 2019 Mar; 107():71-76. PubMed ID: 30500404
    [No Abstract]   [Full Text] [Related]  

  • 8. Explanatory trials versus pragmatic trials.
    Sedgwick P
    BMJ; 2014 Nov; 349():g6694. PubMed ID: 25395503
    [No Abstract]   [Full Text] [Related]  

  • 9. Meeting pragmatism halfway: making a pragmatic clinical trial protocol.
    Rushforth A
    Sociol Health Illn; 2015 Nov; 37(8):1285-98. PubMed ID: 26235211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A guide to research partnerships for pragmatic clinical trials.
    Johnson KE; Tachibana C; Coronado GD; Dember LM; Glasgow RE; Huang SS; Martin PJ; Richards J; Rosenthal G; Septimus E; Simon GE; Solberg L; Suls J; Thompson E; Larson EB
    BMJ; 2014 Dec; 349():g6826. PubMed ID: 25446054
    [No Abstract]   [Full Text] [Related]  

  • 11. Pragmatic trials revisited: applicability is about individualization.
    Sacristán JA; Dilla T
    J Clin Epidemiol; 2018 Jul; 99():164-166. PubMed ID: 29432859
    [No Abstract]   [Full Text] [Related]  

  • 12. Exploring the pragmatic and explanatory study design on outcomes of systematic reviews of public health interventions: a case study on obesity prevention trials.
    Yoong SL; Wolfenden L; Clinton-McHarg T; Waters E; Pettman TL; Steele E; Wiggers J
    J Public Health (Oxf); 2014 Mar; 36(1):170-6. PubMed ID: 24574064
    [No Abstract]   [Full Text] [Related]  

  • 13. Pragmatic surgical studies: are they the New Gold Standard.
    Simpson AHRW; Frost H; Norrie J
    Bone Joint J; 2018 Nov; 100-B(11):1407-1408. PubMed ID: 30418050
    [No Abstract]   [Full Text] [Related]  

  • 14. Pragmatic clinical trials.
    Macpherson H
    Complement Ther Med; 2004; 12(2-3):136-40. PubMed ID: 15561524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pragmatic patient engagement in designing pragmatic oncology clinical trials.
    Davies-Teye BB; Medeiros M; Chauhan C; Baquet CR; Mullins CD
    Future Oncol; 2021 Oct; 17(28):3691-3704. PubMed ID: 34337970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging electronic health record data for pragmatic randomized trials.
    Roe MT
    Clin Trials; 2020 Aug; 17(4):368-369. PubMed ID: 32668979
    [No Abstract]   [Full Text] [Related]  

  • 17. Recommendations for the design of Phase 3 pharmaceutical trials that are more informative for patients, clinicians, and payers.
    Sonnad SS; Mullins CD; Whicher D; Goldsack JC; Mohr PE; Tunis SR
    Contemp Clin Trials; 2013 Nov; 36(2):356-61. PubMed ID: 23999501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intention to treat analysis versus per protocol analysis of trial data.
    Sedgwick P
    BMJ; 2015 Feb; 350():h681. PubMed ID: 25663096
    [No Abstract]   [Full Text] [Related]  

  • 19. The "pragmatic trial": An essentially contested concept?
    Pawson R
    J Eval Clin Pract; 2019 Dec; 25(6):943-954. PubMed ID: 31313412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods.
    Merrill PD; McClure LA
    Trials; 2015 Nov; 16():523. PubMed ID: 26573840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.